Retatrutide sleep apnea research shows the investigational drug cut breathing interruptions far more than placebo in two 80-week phase 3 trials. It's still not FDA-approved, so TelosRX can't prescribe it, but approved options exist.
If you snore like a leaf blower and wake up tired, this news probably caught your eye. Eli Lilly's sleep apnea data on retatrutide landed in October 2026. Search interest in "retatrutide sleep study" spiked within days.
Here's what the trials actually measured, what they found, and what it means for you right now.
What the Retatrutide Sleep Apnea Trials Measured
The results come from two phase 3 trials published in the New England Journal of Medicine. They're called TRIUMPH-1-OSA and TRIUMPH-2-OSA.
- Who enrolled: adults with moderate-to-severe obstructive sleep apnea and a BMI of 27 or higher.
- The split: TRIUMPH-1-OSA enrolled people without type 2 diabetes. TRIUMPH-2-OSA enrolled people with it.
- Doses tested: once-weekly retatrutide at 4 mg, 9 mg, or 12 mg, versus placebo.
- Length: 80 weeks.
- Main outcome: change in the apnea-hypopnea index (AHI), or breathing pauses per hour of sleep.
Both trials were nested inside Lilly's larger TRIUMPH program. The published trial design paper describes how the program also studies obesity and knee osteoarthritis.
The Headline Numbers at a Glance
Participants started with severe disease. Average AHI was 58.6 events per hour in TRIUMPH-1-OSA and 55.9 in TRIUMPH-2-OSA. For context, 30 or more counts as severe.
| Measure (80 weeks) | TRIUMPH-1-OSA (no diabetes) | TRIUMPH-2-OSA (type 2 diabetes) |
|---|---|---|
| Participants randomized | 243 | 448 |
| Baseline AHI (events/hour) | 58.6 | 55.9 |
| AHI change, 9 mg | −34.3 | −24.7 |
| AHI change, 12 mg | −31.7 | −25.4 |
| AHI change, placebo | −9.9 | −10.3 |
| Mean body-weight change, retatrutide doses | −12.5% to −22.2% | −12.1% to −18.5% |
| Mean body-weight change, placebo | −4.8% | −5.6% |
Source: Grunstein et al., NEJM, published online October 2026. Figures use the trial's primary hybrid estimand.
Coverage of the paper also reported a striking detail. More than half of people on 9 mg or 12 mg cut their AHI by at least 50%. Averages are averages, though. Individual results in the trials varied widely.
What Is Obstructive Sleep Apnea, in Plain English?
Obstructive sleep apnea (OSA) means your upper airway keeps collapsing while you sleep. Each collapse briefly cuts off airflow. Your brain jolts you awake just enough to breathe again.
That can happen dozens of times an hour. You rarely remember it. You just feel wrecked the next day.
Common signs include:
- Loud, choppy snoring
- Gasping or choking during sleep
- Morning headaches
- Daytime sleepiness, even after a "full" night
- A partner who says you stop breathing
Only a sleep study can diagnose OSA. If those signs sound familiar, start there.
Why a Triple Agonist Might Matter for Your Airway
Retatrutide activates three hormone receptors: GLP-1, GIP, and glucagon. That's why it's called a "triple agonist," or triple-target drug.
Excess weight around the neck and upper body can narrow the airway. Researchers think weight reduction is the main driver of the AHI changes. The trials also reported lower hypoxic burden, a measure of oxygen dips during sleep.
Want the full mechanism? Our retatrutide vs tirzepatide comparison breaks down triple versus dual agonists.
Side Effects Reported in the Trials
The most common adverse events were gastrointestinal. That matches what we see with other incretin-based medications.
- Nausea
- Diarrhea
- Constipation
- Indigestion (dyspepsia)
Reports described these as mostly mild to moderate, often during dose increases. Long-term safety beyond 80 weeks is still being studied.
Is Retatrutide FDA-Approved for Sleep Apnea?
No. Retatrutide is investigational. It is not FDA-approved for sleep apnea, weight management, or anything else as of this writing.
The FDA has also said retatrutide cannot be used in compounding. Its statement on unapproved GLP-1 drugs spells this out. So no legitimate pharmacy can sell you compounded retatrutide.
Release-date rumors are everywhere. Consider any specific date you see online a guess until the FDA acts.
What You Can Actually Get Today
Here's the useful part. One medication in this class already has an FDA-approved sleep apnea indication.
In December 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity. That approval was based on the SURMOUNT-OSA trials. Our tirzepatide for sleep apnea research review covers those results.
Curious whether a GLP-1 option fits you? Explore tirzepatide at TelosRX. Any prescription is subject to medical approval by a licensed provider after an asynchronous review of your intake. Compounded tirzepatide is not FDA-approved.
Why Gray-Market "Reta" Is a Bad Bet
Search "reta peptide" and you'll find vials sold "for research use only." That label is doing a lot of heavy lifting.
- No one verifies the vial actually contains retatrutide.
- No one verifies the dose, sterility, or storage.
- No provider screens you for risks before you inject.
The trial results came from pharmaceutical-grade drug, careful dose steps, and close monitoring. A mystery vial gives you none of that.
Don't Ditch Your CPAP Yet
If you already use CPAP, keep using it. Positive airway pressure works tonight, while weight changes take months.
Medication and CPAP aren't rivals. Many people may end up using both for a while. If your weight changes a lot, ask your doctor about a repeat sleep study before changing anything.
For a deeper look at the broader program, see our retatrutide clinical trial results breakdown.
Frequently Asked Questions
Does retatrutide help sleep apnea?
In two phase 3 trials, retatrutide lowered the apnea-hypopnea index much more than placebo over 80 weeks. Participants had moderate-to-severe obstructive sleep apnea and excess weight. That is strong early evidence. It is still investigational, though, and not FDA-approved for sleep apnea or any other use.
What is the Eli Lilly retatrutide sleep study?
It refers to TRIUMPH-1-OSA and TRIUMPH-2-OSA, two Lilly-funded phase 3 trials published in the New England Journal of Medicine in October 2026. They compared weekly retatrutide at 4, 9, or 12 mg with placebo over 80 weeks. Adults with sleep apnea enrolled, with and without type 2 diabetes.
When will retatrutide be available?
No one can give you a firm date yet. Retatrutide must complete FDA review before any pharmacy can dispense it. Until approval, it is only available inside clinical trials or formal company access programs. Consider any online release date speculation. Avoid sellers claiming they have it now.
Can a compounding pharmacy make retatrutide?
No. The FDA has stated that retatrutide cannot be used in compounding under federal law. A pharmacy offering compounded retatrutide is not operating within the rules. Products labeled research use only are not meant for people, and their contents, dose, and sterility are unverified.
Is there an FDA-approved medication for sleep apnea?
Yes. In December 2024 the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity. CPAP and other airway therapies also remain standard options. Your provider can help you weigh which approach fits your diagnosis, health history, and goals.
Does weight loss make sleep apnea go away?
Sometimes it improves a lot, but it does not always disappear. Weight is one driver of airway collapse, not the only one. In the retatrutide trials, many people improved, yet results varied. Only a repeat sleep study can tell you where you stand after major weight change.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.